Gleevec and Ih - a phase IV clinical study of FDA data
Summary:
We study 40,843 people who take Gleevec (imatinib mesylate) or have Ih. No report of Ih is found in people who take Gleevec.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
What is Gleevec?
Gleevec has active ingredients of imatinib mesylate. It is often used in chronic myelogenous leukemia (cml). eHealthMe is studying from 35,415 Gleevec users. Check the latest studies of Gleevec.
What is Ih?
Ih is found to be associated with 342 drugs and 914 conditions by eHealthMe. Check the latest studies of Ih.
No report is found.
Do you take Gleevec and have Ih?
- Check whether Ih is associated with a drug or a condition (FREE)
- Predict drug outcomes for up to one year with AI (FREE)
- Get an AI agent to monitor your drugs continuously (FREE)
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Gleevec:
- Gleevec (35,415 reports)
Ih treatments and more:
- Ih (5,428 reports)
How severe was Ih and when was it recovered:
Expand to all the drugs that have ingredients of imatinib mesylate:
Browse all side effects of Gleevec:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Ih:
Browse all the conditions that are associated with Ih:
How the study uses the data?
The study uses data from the FDA. It is based on imatinib mesylate (the active ingredients of Gleevec) and Gleevec (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Ziprasidone Hydrochloride cause Neuroleptic Malignant Syndrome? - 5 seconds ago
- Drug interactions of Tegretol and Prograf - 9 seconds ago
- Levoleucovorin Calcium and Malignant Neoplasm Progression for Women aged 60+ - 11 seconds ago
- Drug interactions of Procardia and Advair Diskus 100/50 - 30 seconds ago
- Could Phentermine cause Cardiac Disorder? - 36 seconds ago
- Drug interactions of Daypro and Thalidomide - 44 seconds ago
- Drug interactions of Fenofibrate and Arthrotec - 49 seconds ago
- Could Candesartan Cilexetil cause Lower Respiratory Tract Infection? - 55 seconds ago
- Viral Upper Respiratory Tract Infection and drugs of ingredients of insulin aspart recombinant - a minute ago
- Drug interactions of Magnesium Sulfate and Saccharomyces - a minute ago